Format

Send to

Choose Destination
J Hematol Oncol. 2008 Oct 29;1:20. doi: 10.1186/1756-8722-1-20.

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting.

Author information

1
Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada. lim.che.kang@sgh.com.sg

Abstract

This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.

PMID:
18959794
PMCID:
PMC2647552
DOI:
10.1186/1756-8722-1-20
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center